Fungal complications with the new coronavirus infection COVID-19

BACKGROUND: The growth of fungal pathology observed in the last decade, including life-threatening invasive mycoses, is associated with spread immunodeficiency states various etiologies. COVID-19 pandemic has made a negative contribution, causing significant increase number patients complications.
 AIM: To characterize types complications acute period new coronavirus infection based on an analysis clinical course and therapeutic tactics for managing underlying disease.
 MATERIALS AND METHODS: results bacteriological study 1284 cultures from sputum samples suspected secondary pneumonia are considered. included 404 fungi. picture was carried out 70 localization, who were treated regional covid hospital. This group microbiological examination sputum, bronchoalveolar lavage (BAL), scrapings lesions oropharynx, urine, blood, biopsy autopsy material. conducted April 01, 2020 to December 31, 2021. divided into subgroups depending isolated pathogen: Candida spp. ― 64 patients, fungi (Aspergillus Mucor spp.) 6 patients; outcome disease: favorable 66, lethal 4.
 RESULTS: In microbial landscape respiratory tract COVID-19, gram-negative flora prevailed, one third represented by During two years pandemic, proportion increased 26.9% 34.2% 2021, while maintaining sensitivity amphotericin B fluconazole most cases. there trend molds species Aspergillus (5 cultures) (1 culture).
 Typical were: candidiasis stomatitis caused albicans (71%), other urogenital localizations form candiduria (20%), lung damage mixed viral-fungal etiology cases, leading death due mycosis. Only 57.1% combinations bacterial 42.9%. Candidiasis diagnosed average day 11.61.08 which corresponded days 2-3 hospitalization. Preceding outpatient treatment, antibiotics hormonal therapy glucocorticosteroids. Urogenital 17.75.17 illness, second week hospital treatment (8.03.11 days). Fungal determined 18.54.33 hospitalization against background intensive immunosuppressive therapy.
 CONCLUSION: Risk factors development age older than 50 years, overweight hypertension, uncontrolled use glucocorticosteroids at prehospital stage. Mycoses recorded both severe moderate COVID-19. An additional factor their disease. formidable complication worsening prognosis survival, addition spp., Mucor, as well fungal-bacterial associations tissue.
 context ongoing SARS-CoV-2 immunomodulatory agents, combined corticosteroids targeted drugs, it important develop risk-based approach diagnosis risk generalized mycoses.